Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
Authors:
Open Access
- 17 October 2022
- journal article
- research article
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 11 (1) , 1-9
Abstract
Background: Long-term outcome is unfavourable for relapsed/refractory (r/r) lymphoma patients who are resistant to salvage chemotherapy, even after subsequent autologous stem-cell transplantation (ASCT). Although anti-CD30 chimeric antigen receptor (CAR30) T-cell therapy induces high response rates in these patients, the duration of response is relatively limited. Methods: This open-label, single-center and single-arm pilot study investigated the safety and efficacy of ASCT in tandem with CAR30 T-cell infusion in r/r CD30+ lymphoma. The primary endpoint was safety and key secondary endpoint was overall response rate, overall survival, progression-free survival, and duration of response. Results: Five classical Hodgkin lymphoma (cHL) patients and 1 anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) patient were enrolled. The median age was 24 years. No patient had prior ASCT. Three patients (50.0%) relapsed for ≥ 2 times and 3 patients (50.0%) had primary refractory diseases. All had a Deauville score of 4 or 5, and 5 patients (83.3%) had a stable or progressive disease (SD/PD) at enrollment. All patients received myeloablative chemotherapy and infused CD34-positive hematopoietic stem cells (HSCs) and CAR30 T cells in tandem, with a median dose of 3.9 × 106/kg and 7.6 × 106/kg, respectively. Five paitents presented with cytokine release syndrome (CRS), all of which were grade 1. No neurotoxicity was observed. All patients had successful HSCs engraftment and reached an objective response, including 5 (4 cHL and 1 ALCL, 83.3%) with a complete response (CR) and 1 with a partial response (PR). With a median follow-up of 20.4 (range, 12.1–34.4) months, all remained alive and maintained their responses. Conclusion: Our work demonstrates the combined administration of ASCT and CAR30 T-cell therapy is well-tolerate and highly effective in r/r cHL and ALCL, even in PET-positive or chemorefractory patients who are expected to have inferior outcome after ASCT, although further large-scaled validation in prospective clinical trial is warranted. Trial registration The trial was registered with the Chinese Clinical Trial Registry (ChiCTR, number ChiCTR2100053662).Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81830008, 82070211)
- National High Technology Research and Development Program of China (863 program 2014AA020532)
- Milstein Medical Asian American Partnership Foundation (2018 MMAAP Foundation Hematology Fellowship Award)
- Young Top-notch Talent Cultivation Program of Hubei Province
This publication has 25 references indexed in Scilit:
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHLBlood, 2018
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature Medicine, 2018
- Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapyBlood, 2018
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytesJournal of Clinical Investigation, 2017
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I TrialClinical Cancer Research, 2017
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaBlood, 2016
- Long‐term survival in young and middle‐aged Hodgkin lymphoma patients in Sweden 1992–2009—trends in cure proportions by clinical characteristicsAmerican Journal of Hematology, 2015
- Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphomaBlood, 2012
- Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapyCurrent Opinion in Immunology, 2005